Yourgene Health
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Yourgene Health generated cash of -$3,820,287, which is less than the previous year. Cash used in financing activities reached the amount of $15,496,138 last year. Net change in cash is therefore $4,231,321.
Cash Flow
| 2010 | -2.57M | -629K | 6.43M |
|---|---|---|---|
| 2011 | -2.59M | -918K | 1.20M |
| 2012 | -1.85M | -398K | 1.21M |
| 2016 | -7.04M | -1.13M | 10.80M |
| 2018 | -9.57M | -634.15K | 9.18M |
| 2020 | -2.07M | -9.02M | 12.61M |
| 2021 | -3.82M | -7.44M | 15.49M |
YGEN.L Cash Flow Statement (2010 – 2020)
| 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.76M | 1.25M | 1.30M | 2.70M | 1.62M | 3.69M | 432K |
Operating activities | |||||||
Net income | -12.00M | -3.38M | -9.48M | -12.11M | -4.90M | -5.82M | -5.66M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 3.24M | 2.09M | 1.20M | 557.32K | 3.18M | 3.23M | 3.01M |
Stock-based compensation expense | 801.88K | 1.60M | 144.24K | 234.59K | 195K | 575K | 532K |
| Deferred income tax benefit | 801.88K | 1.60M | 144.24K | 234.59K | 195K | 575K | 532K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -1.52M | 26.99K | 151.15K | -11.36K | 0 | 0 | 16K |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -3.82M | -2.07M | -9.57M | -7.04M | -1.85M | -2.59M | -2.57M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | -475.38K | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.84M | -1.36M | -163.26K | -1.14M | -398K | -587K | -630K |
Acquisitions Net | -3.60M | -7.68M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -7.44M | -9.02M | -634.15K | -1.13M | -398K | -918K | -629K |
Financing activities | |||||||
Common Stock Issued | 16.18M | 13.34M | 0 | 7.71M | 1.23M | 1.30M | 6.59M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -320.86K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 15.49M | 12.61M | 9.18M | 10.80M | 1.21M | 1.20M | 6.43M |
Net Change In Cash | 4.23M | 1.51M | -1.01M | 2.62M | -1.06M | -2.07M | 3.26M |
Cash at end of period | 6.99M | 2.76M | 282.43K | 5.33M | 555K | 1.62M | 3.69M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |